Advertisement
Skip to Content
Morningstar

Alnylam Pharmaceuticals Inc ALNY Stock Quote

Morningstar Rating
| Rating as of

NASDAQ: ALNY

Last close prices updated as of Jan 27, 2023, 12:27 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 231.59
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Mid Growth
  • Day Range 225.52  –  231.59
  • Year Range 117.58  –  242.97
  • Market Cap 28.1292 Bil
  • Volume / Avg 168,568.0 /  781,193.3
  • Price / Sales 29.12
  • Price / Book 142.92
  • Forward Div Yield —
  • Trailing Div Yield —

Morningstar‘s Stock Analysis ALNY

Valuation
Currency in —
Is it the right time to buy or sell?
Find out with Morningstar Investor
Is it the right time to buy or sell?
Find out with Morningstar Investor

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

Capital Allocation

INVESTOR

Alnylam Reports Positive Phase 3 Results for Patisiran; Raising FVE on Improved Outlook

Rachel Elfman Equity Analyst

Business Strategy and Outlook

| Rachel Elfman |

Alnylam Pharmaceuticals is a pioneer in designing therapeutics based on RNA interference, or RNAi, a mechanism that occurs naturally in cells and silences overexpressed genes, which often cause protein misfolding and/or protein accumulation. Alnylam seeks to capitalize on the therapeutic potential of RNAi by creating small interfering RNA, or siRNA, that can treat diseases at the genetic level. When siRNA reaches its intended target, it can silence the gene that it contains code for, making it a potentially game-changing technology for difficult to treat diseases caused by genetic mutations.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics ALNY

More

Company Profile ALNY

Business Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Contact
675 West Kendall Street, Henri A. Termeer Square
Cambridge, MA, 02142
Sector Healthcare
Industry Biotechnology
Employees 1,665

Related Articles ALNY

Our Picks

6 Undervalued Biotech Stocks for 2023

These stocks from the Morningstar US Biotechnology Index look cheap.
Margaret Guidici
Market Update

The Best- and Worst-Performing Stocks: Q3 2022

Solar stocks shine, and retail remains buoyant. Chinese tech names and European healthcare get battered.
Jakir Hossain
Market Update

Markets Brief: As Stocks Hold Recent Gains, CPI Report Ahead Could Set the Tone for the Fed

Oil stocks fall as crude oil prices decline. Uber and Lyft rally on solid earnings results.
Jakir Hossain
Market Update

Markets Brief: Will Bad News Start to Be Good News for Stocks?

Jobs report ahead. Key proxy votes coming at Google and Walmart.
Tom Lauricella
Market Update

Markets Brief: There's Good News In Fed Rate Hikes

Another rate hike is in sight, but that's good for savers. Chinese stocks Pinduoduo, JD.com bounce. Tesla, Amazon shares slide.
Jakir Hossain
Our Picks

10 Promising Stocks to Consider

These companies are growing their competitive advantages--and their stocks are undervalued.
Susan Dziubinski
Stock Strategist

Moderna's Innovation Still Building a Moat

The company's COVID-19 vaccine has shown the vast potential of its mRNA technology.
Karen Andersen
Fund Spy

An Excellent Choice for Broad Exposure to Healthcare

Gold-rated Vanguard Health Care benefits from an experienced manager.
Dan Culloton

Related News ALNY

More

FAQs for Alnylam Pharmaceuticals Inc Stock

No. ALNY does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

ALNY’s market cap is 28.13 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

ALNY’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

ALNY’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare ALNY’s historical performance against its industry peers and the overall market.